John H . Farley, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Books

• Emerging Therapeutic Targets in Ovarian Cancer
  Farley John, Discovery of Novel Targets [Book Chapter] 2011
• Cancer Treatment and Research
  Farley John, Novel Therapeutic Targets [Book Chapter] 2009
• Pathway Analysis for Drug Discovery
  Farley John, Whole‐Genome Expression Profiling of Papillary Serous Ovarian Cancer: Activated Pathways, Potential Targets, and Noise [Book Chapter] 2008

Publications

• Gynecologic oncology
  Kopelman Zachary A., Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials
  183, p. 103 - 114 2024
• Journal of clinical oncology
  Arend Rebecca C., Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018), p. JCO2202915 - JCO2202915 2023
• Journal of minimally invasive gynecology
  Stewart Chelsea, Factors associated with inpatient narcotic medication usage after robotic assisted laparoscopy 2023
• Journal of geriatric oncology
  Moore Madison S., Robotic-assisted gynecologic surgery in an older population: A comparison study
  14:6, p. 101533 - 101533 2023
• Gynecologic oncology reports
  Schink Julian, 36 Mutational landscape of low-grade serous carcinoma of the ovary
  44, p. S18 - S19 2022
• Gynecologic oncology reports
  Garg Ruchi, 6 Racial differences in the mutational landscape of serous endometrial cancer
  44, p. S3 - S4 2022
• Gynecologic oncology reports
  Garg Ruchi, 37 Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race
  44, p. S19 - S19 2022
• Gynecologic oncology
  Sitler Collin, Do U.S. Screening Guidelines Contribute to Higher Stage and Worse Survival in our Youngest and Oldest Cervical Cancer Patients? (019)
  166, p. S14 - S15 2022
• Journal of clinical oncology
  Schink Julian C., Racial differences in the mutational landscape of serous endometrial cancer
  40:16_suppl, p. 5600 - 5600 2022
• Journal of clinical oncology
  Schink Julian C., Mutational landscape of low-grade serous carcinoma of the ovary
  40:16_suppl, p. 5578 - 5578 2022
• Journal of clinical oncology
  Garg Ruchi, Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race
  40:16_suppl, p. e17590 - e17590 2022
• Gynecologic oncology
  Jokajtys Suzanne, P9 Mixed endometrial cancer a rare histology with the largest racial disparity in survival
  165, p. S9 - S10 2022
• Gynecologic oncology
  Brooks Sandra E., Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair
  160:2, p. 361 - 363 2021
• Gynecologic oncology
  Brown J., Feasibility of a platform trial in rare gynecologic cancers based on molecular analysis
  159, p. 144 - 145 2020
• Gynecologic oncology
  Crane E.K., Molecular profiling in a large cohort of gynecologic neuroendocrine tumors
  159, p. 262 - 262 2020
• Tewari Krishnansu S, Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study 2020
• Gynecologic oncology
  Tewari Krishnansu S., BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY
  159:1, p. 79 - 87 2020
• Journal of clinical oncology
  Brown Jubilee, Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers
  37:15_suppl, p. e14585 - e14585 2019
• Gynecologic oncology
  Konstantinopoulos Panagiotis A., Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
  150:1, p. 9 - 13 2018
• Gynecologic oncology
  Oliver Kate E., An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
  147:2, p. 243 - 249 2017
• Gynecologic oncology
  Moreno A., Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
  147:1, p. 203 - 203 2017
• Gynecologic oncology
  Barnes Dominique, Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
  147:1, p. 215 - 215 2017
• Cancer
  Dalton H. J., Racial Disparities in Cervical Cancer: Worse than we Thought
  123:6, p. 915 - 916 2017
• European journal of gynaecological oncology
  Niu J., Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer
  38:1, p. 40 - 44 2017
• Gynecologic oncology research and practice
  Minion Lindsey E., Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
  3:1, p. 4 - 4 2016
• Molecular cancer therapeutics
  Weiss Glen J., Abstract A50: Phase Ib/II study of pembrolizumab plus chemotherapy: Initial results of metastatic cancer patients
  14:12_Supplement_2, p. A50 - A50 2015
• Cancer Causes & Control
  Best Lyle G., Association of diabetes and cancer mortality in American Indians: the Strong Heart Study
  26:11, p. 1551 - 1560 2015
• Obstetrics and gynecology (New York. 1953)
  Chase Dana M, Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors
  126:4, p. 792 - 802 2015
• Clinical cancer research
  Ramos Pilar, Abstract POSTER-BIOL-1327: Small cell carcinoma of the ovary, hypercalcemic type displays frequent inactivating germline and somatic mutations in SMARCA4
  21:16_Supplement, p. POSTER-BIOL-1327 - POSTER-BIOL-1327 2015
• Journal of clinical oncology
  Niu Jiaxin, Platinum-gemcitabine-bevacizumab (PGA) for platinum-resistant/refractory recurrent ovarian cancer
  33:15_suppl, p. e16534 - e16534 2015
• International Journal of Gynecological Cancer
  Gourley C., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas
  24:9 Suppl 3, p. S9 - 13 2014
• Cancer research (Chicago, Ill.)
  Ramos Pilar, Abstract LB-202: The rare, highly malignant small cell carcinoma of the ovary displays common inactivating germline and somatic mutations in the tumor suppressor SMARCA4
  74:19_Supplement, p. LB-202 - LB-202 2014
• Gynecologic oncology research and practice
  Foss Cassandra D, Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
  1:1, p. 4 - 4 2014
• Gynecologic oncology
  Oliver K.E., An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group (GOG) experience
  133, p. 26 - 27 2014
• Nature Genetics
  Ramos Pilar, Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
  46:5, p. 427 - 429 2014
• Gynecologic Oncology
  Collins Yvonne, Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology
  133:2, p. 353 - 361 2014
• Gynecologic Oncology
  Miller Caela R., MEK1/2 inhibitors in the treatment of gynecologic malignancies
  133:1, p. 128 - 137 2014
• Rare diseases (Austin, Tex.)
  Ramos Pilar, Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
  2:1, p. e967148 - e967148 2014
• Supportive care in cancer
  Craig Christine D, Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment
  22:1, p. 279 - 287 2014
• Gynecologic oncology
  Craig C., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Gynecologic oncology
  Craig C., Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry
  130:1, p. e163 - e163 2013
• Gynecologic oncology
  Craig C., Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study
  130:1, p. e31 - e32 2013
• Gynecologic oncology
  Miller C., An evaluation of molecular markers that predict maximal surgical cytoreduction: A Gynecologic Oncology Group trial
  130:1, p. e20 - e20 2013
• Journal of clinical oncology
  Farley John H., An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience
  31:15_suppl, p. 5534 - 5534 2013
• The lancet oncology
  Farley John, Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
  14:2, p. 134 - 140 2013
• Critical Reviews in Oncology/Hematology
  Monk Bradley J., Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
  86:2, p. 161 - 175 2013
• Gynecologic oncology
  Moore Kathleen N., A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
  127:3, p. 456 - 461 2012
• Cancer research (Chicago, Ill.)
  Farley John H., Abstract CT-05: A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum
  72:8_Supplement, p. CT-05 - CT-05 2012
• Gynecologic Oncology
  Farley John H., American Society of Clinical Oncology 2012 Annual Meeting update: Summary of selected gynecologic cancer abstracts
  126:3, p. 319 - 324 2012
• Journal of reproductive medicine
  Larsen Wilma I, Risk factors for late postpartum preeclampsia
  57:1-2, p. 35 - 38 2012
• Clinical ovarian cancer and other gynecologic malignancies
  Boruta David, PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
  4:2, p. 70 - 73 2011
• Gynecologic oncology
  Oliver Kate E., Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment
  123:1, p. 76 - 81 2011
• Gynecologic oncology
  Hamilton Chad A., The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study
  122:3, p. 521 - 526 2011
• Journal of clinical oncology
  Oliver K. E., The presence of racial disparities in histopathologic characteristics of uterine cancer in an equal-access environment
  29:15_suppl, p. 5094 - 5094 2011
• Gynecologic oncology
  Farley John, Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
  121:2, p. 303 - 308 2011
• Gynecologic oncology
  Farley John, Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study
  121:2, p. 395 - 401 2011
• Journal of clinical oncology
  Matei Daniela, Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
  29:1, p. 69 - 75 2011
• Journal of clinical oncology
  Farley J. H., Regulation of proliferation in endometrial carcinoma cell line by the epidermal growth factor receptor and estrogen receptor beta
  28:15_suppl, p. 5087 - 5087 2010
• Gynecologic oncology
  Farley John, Trial design for evaluation of novel targeted therapies
  116:2, p. 173 - 176 2010
• Oncology & Hematology Review (US)
  Oliver Kate E, Cisplatin plus Cetuximab in the Treatment of Recurrent and Persistent Cancers of the Cervix
  6, p. 45 2010
• International journal of gynecological cancer
  Na Young-Jeong, Ovarian Cancer Markers of Response
  19:11 Suppl 2, p. S21 - S29 2009
• Cancer
  Farley John H., Race Does Not Impact Outcome for Advanced Ovarian Cancer Patients Treated With Cisplatin/Paclitaxel An Analysis of Gynecologic Oncology Group Trials
  115:18, p. 4210 - 4217 2009
• Gynecologic oncology
  Farley John, Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study
  113:3, p. 341 - 347 2009
• Journal of clinical oncology
  Farley J. H., Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group
  27:15_suppl, p. 5521 - 5521 2009
• Clinical ovarian cancer and other gynecologic malignancies
  Farley John, CON: Therapy for a Patient with Platinum–Resistant/Refractory Ovarian Cancer Should Not Be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
  1:2, p. 99 - 103 2008
• Gynecologic oncology
  Hamilton Chad A., Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
  111:3, p. 530 - 532 2008
• Gynecologic oncology
  Darcy Kathleen M., Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study
  111:3, p. 487 - 495 2008
• Journal of clinical oncology
  Farley J. H., Ethnicity and clinical outcome for advanced epithelial ovarian cancer patients treated by standard cisplatin/paclitaxel chemotherapy: A combined analysis of gynecologic oncology group clinical trials
  26:15_suppl, p. 5573 - 5573 2008
• Cell research
  Farley John, Genomic analyses of epithelial ovarian cancer
  18:5, p. 538 - 548 2008
• The Surgical clinics of North America
  Stany Michael P., Complications of Gynecologic Surgery
  88:2, p. 343 - 359 2008
• Cell Res
  Farley John, Genomic analysis of epithelial ovarian cancer
  18:5, p. 538 - 548 2008
• Disease markers
  Farley John, Cell cycle and related protein
  23:5-6, p. 433 - 443 2007
• Gynecologic oncology
  Farley John, Biomarkers and clinical trial design
  103:2, p. 3 - 5 2006
• Journal of reproductive medicine
  Farley John H, Far forward gynecologic care of the female soldier
  51:1, p. 31 - 35 2006
• Journal of clinical oncology
  Farley J. H., A randomized double-blind phase II evaluation of the cyclooxygenase-2 protein inhibitor celecoxib in treating severe dysplasia of the cervix
  23:16_suppl, p. 5106 - 5106 2005
• Clinical obstetrics and gynecology
  Farley John, Current techniques for the evaluation of abnormal cervical cytology
  48:1, p. 133 - 146 2005
• Current oncology reports
  Farley John H, Biologic directed therapies in gynecologic oncology
  5:6, p. 459 - 467 2003
• Gynecologic oncology
  Robison Steven W., Ethnic Differences in Survival among Pacific Island Patients Diagnosed with Cervical Cancer
  84:2, p. 303 - 308 2002
• Gynecologic oncology
  Nycum L.R., The Role of p27 in Endometrial Carcinoma
  81:2, p. 242 - 246 2001
• Cancer
  Farley John H, Equal care ensures equal survival for African-American women with cervical carcinoma
  91:4, p. 869 - 873 2001
• Gynecologic oncology
  Farley John H., Age-Specific Survival of Women with Endometrioid Adenocarcinoma of the Uterus
  79:1, p. 86 - 89 2000
• Gynecologic oncology
  Farley John, Endocervical Cancer Is Associated with an Increase in the Ligands and Receptors for Transforming Growth Factor-β and a Contrasting Decrease in p27Kip1
  78:2, p. 113 - 122 2000
• Analytical and quantitative cytology and histology
  Farley J, Transferrin in normal and neoplastic endocervical tissues: distribution and receptor expression
  20:4, p. 238 - 249 1998
• Military medicine
  Farley John H., Chest Wall Tumors: Experience with 58 Patients
  156:8, p. 413 - 415 1991
• Military medicine
  Farley J. H, Chestwall tumors : experience with 58 patients
  156:8, p. 413 - 415 1991